title: [Improved results in the treatment of acute monoblastic leukemia: analysis of 91 patients treated in the 01 AM 81 protocol].
abstract: A total of 91 patients with acute monoblastic leukemia (AML) were treated following two induction regimens (ARA-C + RBZ, with of without CPA), and a unique maintenance therapy (CNS prophylaxis and reinductions every 6 weeks, for 36 months). Complete remission (CR) was obtained in 84% of patients. The only prognostic factor significantly influencing the CR rate was age, with 92% for the less than 40 years group and 75% for the greater than or equal to 40 years group. CR was not influenced by sex, tumoral syndrome, leukocytosis, cytological subclassification (M5A, M5B), or induction regimen with or without CPA. The duration of CR in these forms which have a traditionally poor prognosis, was no different from other forms of AML (21 months), and the disease-free survival at 50 months was 45%. These results, pertaining to the largest published series treated by the same protocol, are the best reported in literature and confirm the role of induction and maintenance therapy in CR.
authors.affiliation: Institut de Recherches sur les Leucémies et les Maladies du Sang, Hôpital Saint-Louis, Paris.
authors.forename: S
authors.initials: S
authors.lastname: Collado
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: M T
authors.initials: MT
authors.lastname: Daniel
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: D
authors.initials: D
authors.lastname: Bordessoule
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
authors.forename: L
authors.initials: L
authors.lastname: Degos
authors.forename: G
authors.initials: G
authors.lastname: Schaisson
authors.forename: M
authors.initials: M
authors.lastname: Boiron
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D011897:Random Allocation
chemical_list: D000903:Antibiotics, Antineoplastic; D003561:Cytarabine; D003520:Cyclophosphamide; C002205:zorubicin; D003630:Daunorubicin
vernacular_title: Amélioration des résultats du traitement des leucémies aiguës monoblastiques: analyse de 91 malades traités dans le protocole 01 AM 81.